PDCD1 and systemic lupus erythematosus: Given that anti-PD-1 therapy expands PD-1+CD8+ T cells in cancer 34 and can paradoxically induce lupus-like autoimmunity 21, we hypothesized that activating the PD-1 pathway could mitigate LN.